Intellectual Property

How does LondonPharma create Intellectual Property?

REPURPOSING is the application of the existing drug (knowledge of its physico-chemical properties) + (combined with) carrier (knowledge of its physico-chemical properties) + (combined with) mode of delivery (spray) + LondonPharma’s know how that enables the change in therapeutic use or enhanced use.

It is the company’s ability to combine these aspects which creates Intellectual Property.

Artemisinins

LondonPharma has a robust portfolio of patents covering the use of artemisinins in sublingual and other formulations.

LondonPharma has a patent for the treatment of a neoplastic disease using artemisinins in a medium chain triglyceride carrier applied transmucosally. This patent was filed in 2010 and is being granted in many countries around the world rapidly.

LondonPharma has a patent for the composition of selected artemisinins in a medium chain triglyceride carrier applied transmucosally. This patent has a claim for the treatment of a disease responsive to the selected artemisinins. This patent is also gaining grant worldwide.

Carrier

LondonPharma has a patent covering its medium chain triglyceride carrier with a range of compounds.

Device

The repurposed drugs work in a range of commercially available, multi-shot devices. LondonPharma has developed a single-shot sublingual spray delivery system for which the patent is pending.

Updated: 13/7/14

Print this page

LondonPharma intends to prosecute its intellectual property in all markets of interest.

LondonPharma will vigorously defend its intellectual property.